Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from an overweight rating to an equal weight rating in a report issued on Thursday, MarketBeat.com reports ...
On Feb. 24, from west to east, you can see Mercury, Saturn, Neptune, Venus, Uranus, Jupiter and Mars, all spanning 117.5°, plus Earth under your feet—all eight known planets of our solar system!
On Feb. 24, from west to east, you can see Mercury, Saturn, Neptune, Venus, Uranus, Jupiter and Mars, all spanning 117.5°, ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
The FDA has approved suzetrigine, a new, non-opioid medication for adults with moderate to severe acute pain.
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback